Chemical tracer diffusion of Sr and Co in polycrystalline Ca-deficient CaMnO3-δ with CaMn2O4 precipitates.
»
Chemical tracer diffusion of Sr and Co in polycrystalline Ca-deficient CaMnO3-δ with CaMn2O4 precipitates.
Diffusivity in the A- and B-sites CaMnO3 polycrystalline perovskite-δ-deficient Ca and spinel CaMn2O4 (marokite) as a secondary phase was studied using chemical tracers and secondary ion mass spectrometry (SIMS) equipped with electron probe microanalysis (EPMA). a thin film containing a chemical tracer Sr and Co is deposited on the polished surface of the polycrystalline composite samples followed by annealing at 800-1200 ° C for 96 hours. diffusion profile for each tracker is determined by SIMS, followed by calculation of the diffusion coefficient by fitting to the appropriate model.
Trackers Sr showed diffusion especially grating, with the activation energy of 210 ± 30 kJ mol-1, while the Co tracker shows the combination of lattice and enhanced grain boundary diffusion, with an activation energy of 270 ± 30 kJ mol-1 and 380 ± 40 kJ mol-1, each
The diffusivity can be used to predict the lifetime of the interdiffusion and the junctions between the n-type or CaMnO3 CaMnO3-δ-δ / CaMn2O4 composite and interlayers metallization or p-type material in the leg oxide thermoelectrics. In particular, relatively high diffusivity in polycrystalline CaMnO3 effective co-δ may play a role in reporting the rapid formation of a secondary phase (Ca3Co2-yMnyO6) between Ca3Co3.92O9 + p-type and n-type δ-δ CaMnO3 in a direct pn junction thermoelectric , A quick search in the database of scientific publications have demonstrated how the use of CRISPR-Cas genome engineering has considerably expanded edition, and growing importance, in modern molecular biology. Only in pub-med Platform, the search term gives more than 3000 results.
In particular, in Drug Discovery, Medicinal Chemistry and Chemical Biology in general CRISPR method may have multiple applications. Some of these applications are: resistance-election study of organic compounds lead antimalarial; druggability investigation; the development of animal models to test chemical compounds, etc. In this paper, we offer a review of the relevant scientific literature illustrated with specific examples of the application of CRISPR techniques for medicinal chemistry and chemical biology. We also present a general overview of the main trends regarding legal and ethical methods of genome editing.
Chemical tracer diffusion of Sr and Co in polycrystalline Ca-deficient CaMnO3-δ with CaMn2O4 precipitates.
active modulation of carbonate chemistry calcifying fluid (δ11B, B / Ca) and seasonal invariant coral calcification in the sub-tropical boundary.
Coral calcification depends on both the supply of dissolved inorganic carbon (DIC) and the up-regulation of pH on calcifying fluid (cf). Using geochemical proxies (δ11B, B / Ca, Sr / Ca, Li / Mg), we show seasonal changes in pHcf and DICcf to Acropora yongei and Pocillopora damicornis grown in-situ on Rottnest Island (32 ° S) in Western Australia , Changes in pHcf span of 8:38 in the summer to 8.60 in the winter, while DICcf is 25 to 30% higher during the summer than the winter (× 1.5 × 2 to the sea). Thus, the two variables is up-regulated far above the values of seawater and seasonal out of phase with each other.
Description: A polyclonal antibody against BACE1. Recognizes BACE1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB
Description: A polyclonal antibody against BACE1. Recognizes BACE1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200
Description: A polyclonal antibody against BACE1. Recognizes BACE1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, IF, ELISA;IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/5000
Description: A polyclonal antibody against BACE1. Recognizes BACE1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:2000-1:5000, WB:1:500-1:2000
Description: A polyclonal antibody against BACE1. Recognizes BACE1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:15-1:50
Description: Cerebral deposition of amyloid beta peptide is an early and critical feature of Alzheimer's disease. Amyloid beta peptide is generated by proteolytic cleavage of amyloid precursor protein (APP) by two proteases, one of which is BACE. This protein, a member of the peptidase A1 protein family, is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi.
Description: Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. [UniProt]
Description: Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. [UniProt]
Description: Bace1 (β-secretase 1) is an aspartic protease that is involved in the processing of the Amyloid precursor protein (APP). Cleavage of APP by BACE1 followed by γ-secretase results in β-amyloid peptide production, which ultimately leads toxic Aβ accumulation. In Alzheimer's disease (AD), it has been widely accepted that Aβ aggregation plays a critical role in AD pathogenesis, suggesting that BACE1 could be a potential target to treat AD. The BACE1 FRET Assay Kit is designed to measure BACE1 activity for screening and profiling applications based on fluorescence resonance energy transfer (FRET) using a labeled peptide substrate (below).
Description: Beta-secretase 1 (BACE1) is also known as beta-site APP cleaving enzyme 1 (beta-site amyloid precursor protein cleaving enzyme 1), memapsin-2 (membrane-associated aspartic protease 2), and aspartyl protease 2 (ASP2), β-Secretase , and is a member of the peptidase A1 protein family, BACE1 is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. BACE1 is an aspartic-acid protease important in the pathogenesis of Alzheimer's disease, and in the formation of myelin sheaths in peripheral nerve cells. The transmembrane protein contains two active site aspartate residues in its extracellular protein domain and may function as a dimer. This protease is responsible for the proteolytic processing of the amyloid precursor protein (APP). Generation of the 40 or 42 amino acid-long amyloid-β peptides that aggregate in the brain of Alzheimer's patients requires two sequential cleavages of the APP. Extracellular cleavage of APP by BACE creates a soluble extracellular fragment and a cell membrane-bound fragment referred to as C99. The elevation of BACE1 levels can be induced by amyloid plaques surrounding neurons at early stages of pathology before neuron death occurs, and may drive a positive-feedback loop in AD.
Description: Beta-secretase 1 (BACE1) is also known as beta-site APP cleaving enzyme 1 (beta-site amyloid precursor protein cleaving enzyme 1), memapsin-2 (membrane-associated aspartic protease 2), and aspartyl protease 2 (ASP2), β-Secretase , and is a member of the peptidase A1 protein family, BACE1 is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. BACE1 is an aspartic-acid protease important in the pathogenesis of Alzheimer's disease, and in the formation of myelin sheaths in peripheral nerve cells. The transmembrane protein contains two active site aspartate residues in its extracellular protein domain and may function as a dimer. This protease is responsible for the proteolytic processing of the amyloid precursor protein (APP). Generation of the 40 or 42 amino acid-long amyloid-β peptides that aggregate in the brain of Alzheimer's patients requires two sequential cleavages of the APP. Extracellular cleavage of APP by BACE creates a soluble extracellular fragment and a cell membrane-bound fragment referred to as C99. The elevation of BACE1 levels can be induced by amyloid plaques surrounding neurons at early stages of pathology before neuron death occurs, and may drive a positive-feedback loop in AD.
Description: Beta-secretase 1 (BACE1) is also known as beta-site APP cleaving enzyme 1 (beta-site amyloid precursor protein cleaving enzyme 1), memapsin-2 (membrane-associated aspartic protease 2), and aspartyl protease 2 (ASP2), β-Secretase , and is a member of the peptidase A1 protein family, BACE1 is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. BACE1 is an aspartic-acid protease important in the pathogenesis of Alzheimer's disease, and in the formation of myelin sheaths in peripheral nerve cells. The transmembrane protein contains two active site aspartate residues in its extracellular protein domain and may function as a dimer. This protease is responsible for the proteolytic processing of the amyloid precursor protein (APP). Generation of the 40 or 42 amino acid-long amyloid-β peptides that aggregate in the brain of Alzheimer's patients requires two sequential cleavages of the APP. Extracellular cleavage of APP by BACE creates a soluble extracellular fragment and a cell membrane-bound fragment referred to as C99. The elevation of BACE1 levels can be induced by amyloid plaques surrounding neurons at early stages of pathology before neuron death occurs, and may drive a positive-feedback loop in AD.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human BACE1 . This antibody is tested and proven to work in the following applications:
Description: Human BACE1, also known as beta-site amyloid precursor protein cleaving enzyme 1 and ASP2, GenBank Accession No. NM_012104.4, a.a. 22-460, with C-terminal His-Tag, MW=50 kDa, expressed in HEK293 cells.
Description: A polyclonal antibody against BACE1. Recognizes BACE1 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against BACE1. Recognizes BACE1 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against BACE1. Recognizes BACE1 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human BACE1 / BACE (Internal). This antibody is tested and proven to work in the following applications:
Description: Description of target: Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. ;Species reactivity: Rat;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 6.7 pg/mL
Description: Description of target: Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.39 ng/mL
Description: Description of target: Cerebral deposition of amyloid beta peptide is an early and critical feature of Alzheimer's disease. Amyloid beta peptide is generated by proteolytic cleavage of amyloid precursor protein (APP) by two proteases, one of which is the protein. BACE1, a member of the peptidase A1 protein family, is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi.Cerebral deposition of amyloid beta peptide is an early and critical feature of Alzheimer's disease. Amyloid beta peptide is generated by proteolytic cleavage of amyloid precursor protein (APP) by two proteases, one of which is the protein encoded by this gene. The encoded protein, a member of the peptidase A1 protein family, is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. Four transcript variants encoding different isoforms have been described for this gene.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 0.11ng/mL
Description: Description of target: Bace1 is responsible for the proteolytic processing of the amyloid precursor protein (APP). Bace1 cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: < 12.1pg/mL
Description: Description of target: This gene encodes a member of the peptidase A1 family of aspartic proteases. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature protease. This transmembrane protease catalyzes the first step in the formation of amyloid beta peptide from amyloid precursor protein. Amyloid beta peptides are the main constituent of amyloid beta plaques, which accumulate in the brains of human Alzheimer's disease patients.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.11 ng/mL
Description: Description of target: This gene encodes a member of the peptidase A1 family of aspartic proteases. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature protease. This transmembrane protease catalyzes the first step in the formation of amyloid beta peptide from amyloid precursor protein. Amyloid beta peptides are the main constituent of amyloid beta plaques, which accumulate in the brains of human Alzheimer's disease patients. Homozygous knockout mice for this gene exhibit a wide range of nervous system defects, growth retardation, metabolic abnormalities, and increased neonatal lethality.;Species reactivity: Mouse;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 14.1 pg/mL
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human BACE1 (N-term). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human BACE1 / BACE (C-Terminus). This antibody is tested and proven to work in the following applications:
Description: A Monoclonal antibody against Human BACE1. The antibodies are raised in Mouse and are from clone 3C1C3. This antibody is applicable in WB, FC, ICC, E
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Bace1 - middle region. This antibody is tested and proven to work in the following applications:
Description: Description of target: This gene encodes a member of the peptidase A1 family of aspartic proteases. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature protease. This transmembrane protease catalyzes the first step in the formation of amyloid beta peptide from amyloid precursor protein. Amyloid beta peptides are the main constituent of amyloid beta plaques, which accumulate in the brains of human Alzheimer's disease patients. [provided by RefSeq, Nov 2015];Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.31 ng/mL
The net effect of these counter-cyclical behavior between DICcf and pHcf is that the aragonite saturation state of liquid whitewash (Ωcf) rose ~ 4 times over the values of seawater and ~ 25 to 40% higher during the winter than the summer , Thus, this coral control the chemical composition of the liquid whitewash to help maintain the level of calcification throughout the year in near-constant, despite the seasonal sea water temperature of only ~ 19 ° to 24 ° C. The ability of coral to up-regulate Ωcf is a key mechanism to optimize biomineralization, and thus it is important for the future of coral calcification under high CO2 conditions.
